Cancer

August 13, 2017

Natural product-derived therapy for Chronic Myeloid leukaemia (CML): Artimesinin, isolated from Artemesia Annua L, decreases the expression of Musashi2, inhibits cytosolic aminotransferase BCAT1 expression, decreases the intracellular production of BCAAs (Branched-chain amino acids), increases the expression of tumor suppressor genes, promotes differentiation of CML cells, and inhibits cancer progression in Myeloid leukemia via up-regulation of its target gene, 13/August/2017, 10.08 pm

Introduction: What they say: A study from the Department of Biochemistry-Molecular Biology, Franklin College of Arts and Sciences, The University of Georgia, Athens, Georgia 30602, USA; […]
August 12, 2017

Natural product-derived Combination therapy for Squamous cell carcinoma of head and neck (HNSCC): A therapeutic mix encompassing Ivermectin and 1,25-dihydroxyvitamin D/Cholecalciferol may decrease BMI1 and AP-1 expression, overcome chemotherapeutic resistance, promote chemosensitivity, suppress cancer stem cells in HNSCC, and inhibit lymph node metastasis via down regulation of its target genes, 12/August/2017,  10.43 pm

Introduction: What they say: A study from the Laboratory of Molecular Signaling, Division of Oral Biology and Medicine, Jonsson Comprehensive Cancer Center and Broad Stem Cell Research […]
August 11, 2017

Natural product-derived Anti-AXL therapeutics for enhancing the efficacy of chemotherapies: Ivermectin, the anti-parasitic drug, decreases the expression of the AXL receptor and its activating ligand, GAS6, increases the expression of a number of tumor suppressor genes, increases therapeutic index of anticancer drugs, suppresses tumorigenesis, migration, invasion, and metastasis via up regulation of its target gene, 11/August/2017, 11.41 pm

Introduction: What they say: A study from the Department of Radiation Oncology, Stanford University School of Medicine shows that “Inhibition of the GAS6/AXL pathway augments the efficacy of […]
August 10, 2017

Natural product-derived therapy for therapy-resistant cancers: A therapeutic mix encompassing Phenethyl isothiocyanate (PEITC), β-Cryptoxanthine (BCX) and Berberine (BBR) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via up regulation of its target gene, 10/August/2017, 11.32 pm

Introduction: What they say: A study from Broad Institute, Cambridge, Massachusetts, USA, Howard Hughes Medical Institute, Chevy Chase, Maryland and Department of Chemistry and Chemical Biology, […]